OncoNano Medicine, a Dallas-based biotechnology company, announced a research collaboration with Gilead Sciences to evaluate its ON-BOARD™ drug delivery technology with one of Gilead’s experimental cancer drug candidates. The partnership will study whether ON-BOARD, a polymer-based technology designed to deliver treatments directly into tumors, can improve the drug's stability, selectivity, and effectiveness. OncoNano will receive an upfront payment and may earn additional development, regulatory, and commercial milestone payments, as well as royalties, with potential total payments of up to $300 million if Gilead expands the collaboration to include another drug target.
